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Progress in oncological treatment has led to an improved long-term survival of young male
cancer patients over the last decades. However, standard cancer treatments frequently
implicate fertility-damaging potential. Cryopreservation of sperm is the current standard
option to preserve patient’s fertility after treatment, yet long-term data on usage and
reproductive experiences is still limited. Natural fertility after treatment and especially in
relation to the type of treatment has been poorly analyzed so far. Therefore, we performed
a retrospective survey including male patients with an indication for gonadotoxic treatment
who cryopreserved reproductive material at our institution between 1994 and 2017. Study
questionnaires regarding treatment, material usage, and reproductive outcomes were
sent to eligible patients. Additionally, semen analyses of study participants from the time of
cryopreservation were evaluated. A total of 99 patients were included in the study.
Respondents’ median age was 38.0 years. Most frequent diagnoses were testicular
cancer (29.3%) and lymphoma (26.3%). A further 8.1% suffered from autoimmune
diseases. Testicular cancer patients had a significantly lower pre-treatment median
sperm concentration (18.0 million/ml) compared to non-testicular cancer patients (54.2
million/ml). Until November 2020, the determined sperm usage and cumulative live-birth
rate per couple were 17.2% and 58.8%, respectively. Most sperm users received
treatments with high (40.0%) or intermediate (33.3%) gonadotoxic potential. 20.7% of
all patients reported to had fathered at least one naturally conceived child after treatment,
this being the case especially if they had been treated with less or potentially gonadotoxic
therapies. In conclusion, our findings emphasize the importance of spermNovember 2021 | Volume 11 | Article 7728091
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that the gonadotoxic potential of patients’ treatments could represent a predictive factor
for sperm usage.Keywords: sperm cryopreservation, cancer, fertility preservation, assisted reproduction techniques (ART),
chemotherapy, natural fertility, reproductive outcomes, cancer treatmentINTRODUCTION
Due to advances in both oncological diagnosis and treatment,
over the last few decades the long-term survival of young male
cancer patients has significantly improved. However, standard
cancer treatments – including radiation therapy, classical
cytotoxic substances, and increasingly personalized, modern
approaches – often implicate potential risks for patients’
future fertility.
Several studies have shown reduced semen quality in some
cancer patients even prior to the initiation of their treatment. This
impairment of spermatogenesis, induced by the malignancies
themselves, especially applies to patients with testicular cancer, the
most frequently diagnosed cancer type in young men (1–3). In
addition, various cancer treatments cause damage to
spermatogenesis: Firstly, cytotoxic agents frequently compromise
spermatogenesis, at least temporarily, and in some cases even
induce permanent azoospermia. Among the cytotoxic substances,
most alkylating agents and cisplatin are known to be strongly
gonadotoxic; however, their deleterious effects on spermatogenesis
ultimately depend on drug combination and dosage (4, 5). Secondly,
the irradiation of the radiosensitive testicles deteriorates their
function in a dose dependent way. Doses above four Gy can
cause permanent germ cell defects, and 16 – 20 Gy can lead to
irreversible azoospermia. Although recovery of spermatogenesis is
attainable, it is highly dependent on radiation doses and the number
of cycles conducted, requiring up to five years or even longer. Leydig
cells of adults were observed to be more resistant to radiotherapy,
nevertheless, in some cases testosterone replacement therapy after
gonadal radiation is still necessary (6). Thirdly, conditioning
regimens for hematopoietic stem cell transplantations (HSCT)
have an extremely high gonadotoxicity due to aggressive
chemotherapies and/or total body irradiation (TBI) combinations
(5, 7). Finally, fertility can be reduced after gonadal surgeries, such as
the radical inguinal orchiectomy, which is the mainstay of treatment
for testicular cancer patients. Several studies report adverse effects
on semen parameters and hormonal functions after radical inguinal
orchiectomies (6).
Patients’ fertility after cancer treatment is not predictable.
Therefore, fertility preservation is a primary concern for cancer
patients of reproductive age and should be discussed as early as
possible before treatment is initiated. Currently, the standard
option for fertility preservation in men is cryopreservation of
ejaculated semen (8). The number of cancer patients who
undergo sperm cryopreservation has increased during the last
20 years (1, 9). Regardless, in many countries, pre-treatmentve techniques. HSCT, hematopoietic
rradiation; IQR, interquartile range.
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sperm banking has not been established in clinical practice or is
underutilized when offered (2, 10, 11). Depending on the
country, costs for storage differ (11, 12). In Germany, as of the
beginning of July 2021, the costs of sperm storage for cancer
patients who have to undergo fertility-damaging therapies are
covered by the public health insurance, according to the decision
of the Federal Joint Committee (G-BA).
Reported usage rates of stored material remain low, often less
than 10%, with a slight increase when examining long-term follow-
ups of above 10 years (1, 9, 13–18). Different variables impacting
long-term usage of sperm have been described so far, including age
at the time of cryopreservation, type of cancer, and total number of
cryopreserved spermatozoa (18). Nevertheless, many influencing
factors are still unexplored. After deciding to use the frozen semen,
couples proceed with assisted reproductive techniques (ART) and
achieve parenthood in 35 – 80% of cases (1, 14, 19, 20).
Ample literature on outcomes of sperm cryopreservation in
cancer patients exists, however, various aspects have not yet been
analyzed sufficiently. Data on long-term follow-ups is still limited
and more research is needed to make reliable conclusions about
ART usage and success rates (1, 9, 11, 13–15, 19, 20). Moreover,
studies exploring the relation between different cancer treatment
types, sperm usage, and reproductive outcomes of natural
fertility after treatment are lacking (19, 21–24). In addition,
fertility preservation also concerns young patients affected by
various non-oncological medical conditions. One group in this
context are patients suffering from autoimmune diseases treated
with gonadotoxic immunotherapy or HSCT. To our knowledge,
cryopreservation experiences and outcomes from non-
oncological patients who undergo fertility-damaging treatments
have been barely reported (25).
In order to address the above-mentioned aspects of interest,
and to add new findings to the existing literature, we performed a
questionnaire-based survey of patients who cryopreserved
reproductive material at our institution over a period of 22
years. This study aimed to analyze participants’ usage of stored
material, resulting ART outcomes, and natural reproduction
outcomes after treatment, and to examine these outcomes with
regard to treatment types and their gonadotoxic potential.MATERIALS AND METHODS
Availability of Materials
The study questionnaire and original data underlying the
conclusions listed in the manuscript are included in the
supplementary material; further inquiries can be directed to the
corresponding author.November 2021 | Volume 11 | Article 772809
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The study population included all male patients who
cryopreserved reproductive material at the Cryobank of
Charité – Universitätsmedizin Berlin in the period from February
1994 until November 2017. All oncological and non-oncological
patients with diagnoses requiring potentially gonadotoxic
treatments were considered. Inclusion criteria were an age
above 18 years, patient data available in our patient database and
a German contact address. Deceased patients as well as patients
with unsuccessful cryopreservation were excluded.
A study-specific questionnaire was developed by the
researchers including the following questions: sociodemographic
characteristics (personal data, occupation), questions related to
diagnosis and treatment (disease/treatment as indication for
cryopreservation, type of cancer/other diagnosis, date of initial
diagnosis, type/s of treatment, date/s of treatment, relapses of
disease, current disease status), questions concerning the
cryopreservation (date/s, frequency, indication, time of
cryopreservation in relation to treatment), questions about usage
of stored material (material request, collection date, usage for
ART, successful live-births, unsuccessful ART procedures, usage
planned in future), and questions regarding family and children
[marital status, number of children, characteristics of children
(biological/not biological, type of reproduction, date of birth, sex,
birth weight, height at birth, events during birth, current health
status, date of birth of mother)].
Procedure and Data Management
Our patient database was reviewed to find potential study
participants. Out of 1089 patients, who were listed in the
Cryobank for the mentioned period, 774 were identified as
possible participants. In June and September 2020, the eligible
patients were sent a study pack containing a participant’s
information sheet, a consent form and copy, the study
questionnaire and a pre-paid envelope addressed to the director
of the study. 259 study packs could not be delivered due to outdated
mailing addresses. 515 study packs could bedelivered.A total of 111
questionnaires were completed and returned, yielding a response
rate of 21.5%. Two respondents were relatives of recently deceased
patients and had completed the questionnaires for them. Their data
were excluded from the analysis. Further 10 patients were excluded
because of missing indication for gonadotoxic treatment.
Semen Analyses
Semen analyses at the time of cryopreservation were requested
from our Cryobank for patients included in the study. 82
analyses of ejaculated semen and three analyses of testicular
tissue could be provided. The researchers evaluated sperm
concentration, progressive and total motility (progressive and
non-progressive motility) based on reference parameters from
the World Health Organization (WHO) guidelines of 1999 and
2010, respectively (26, 27).
Data Analysis
Data was entered into a password protected secure database. Not
all respondents replied to all questions. Where possible, missing,Frontiers in Oncology | www.frontiersin.org 3or inconsistent data was revised and completed with data from
our patient database. The number of patients whose data was still
missing after this procedure is indicated and the respective
patients were excluded from percentage calculations. Missing
day or month specifications were replaced with the first day of a
month or the first month of a year, respectively.
Data was analyzed in IBM SPSS Statistics Version 27.
Categorical variables were presented as percentages. Continuous
variables were presented as medians and interquartile range (IQR).
Since the variables did not follow normal distribution, non-
parametric tests were used to compare patient groups (Mann-
Whitney-U-test and Chi-square-test). A p-value <0.05 was
considered as statistically significant. Diagnosis groups were
subsumed into appropriate upper-level groups for statistical testing.
Due to the retrospective design of the study, randomization or
blinding of participants were not applicable. No power
calculation was performed as the sample size directly resulted
from the number of respondents to the questionnaire.RESULTS
Characteristics and Treatments of
Respondents
A total of 99 patients were included in the study. 91 patients (91.9%)
suffered from oncological and 8 patients (8.1%) from non-
oncological diseases. Most frequent diagnoses were testicular
cancer (29.3%) and malignancies of the lymphatic and
hematopoietic tissue (40.4%), as illustrated in Figure 1. All non-
oncological patients were diagnosed with autoimmune diseases
(namely membranous glomerulonephritis (two patients),
neurosarcoidosis, Crohn’s disease, autoimmune thrombocytopenia,
central nervous system vasculitis, systemic lupus erythematosus and
septic granulomatosis). Respondents’ median age at the time of the
survey was 38.0 years (IQR: 31.0 – 46.0 years). Further characteristics
of the participants are shown in Table 1.
The participants received one (60.2%) or multiple (39.8%) of the
following gonadotoxic treatment types: cytotoxic agents
(chemotherapy or immunotherapy), orchiectomy, radiotherapy,
and/or HSCT. Radiation therapy was included as a fertility-
damaging treatment exclusively in case of gonadal irradiation or
TBI as a conditioning regimen for HSCT, meaning that irradiation
of other body parts (13 patients) or unknown areas (9 patients) were
not included. One patient did not undergo the planned treatment
and was excluded from treatment analyses. The fertility-damaging
treatments were classified into four categories depending on their
gonadotoxic potential (Table 2). In total, 89 patients (90.8%) were
treated with cytotoxic agents as part of their therapy regimens. 10
patients did not specify the cytotoxic substances and were excluded
from the treatment classification. Figure 2 illustrates the
distribution of the treatment categories in the study population.
Five patients (5.1%) underwent cryopreservation after treatment
initialization or partial treatment completion. Among them, three
patients had been orchiectomized and two patients had been treated
with chemotherapy prior to cryopreservation.November 2021 | Volume 11 | Article 772809
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Semen analyses of ejaculated sperm at the time of cryopreservation
were available for 82 of 99 patients. Median sperm concentration
[37.9 million/ml (IQR: 17.3 – 93.2 million/ml)], progressive [47.0%
(IQR: 32.0 – 55.0%)] and total sperm motility [56.0% (IQR: 43.3 –
65.0%)] of patients who cryopreserved sperm before initiating
gonadotoxic therapy were normal. The five patients who stored
material after partial treatment completion had a median sperm
concentration of 20.5 million/ml (IQR: 13.2 – 56.6 million/ml),
progressive motility of 32.0% (IQR: 24.0 – 55.0%) and total motility
of 38.0% (IQR: 35.0 – 63.5%).Frontiers in Oncology | www.frontiersin.org 4Pre-treatment semen analyses according to diagnosis groups are
shown in Table 3. Testicular cancer patients had a significantly
lower median sperm concentration [18.0 million/ml (IQR: 9.7 –
37.8 million/ml)] compared to non-testicular cancer patients (54.2
million/ml (IQR: 23.0 – 110.2 million/ml), Mann-Whitney-U-test,
p = 0.003). No significant differences in progressive and total
motility between the two groups were observed (Mann-Whitney-
U-test, p = 0.656 and p = 0.688).
Sperm Usage and ART Outcomes
Overall, 17 patients (17.2%) decided to use their cryopreserved
material for ART procedures. In 13 cases, the reproductive
material was ejaculated sperm, while the reproductive material
remained unknown in the other four cases. The median age was
32.0years (IQR:27.0–36.5years) at the timeof cryopreservation.No
significant difference from the median age at the time of
cryopreservation of patients who did not use their material [27.0
years (IQR: 20.0 – 35.3 years)] was observed (Mann-Whitney-U-
test, p = 0.135). Table 4 summarizes the diagnosis groups and
treatment categories of patient groups who used and did not use the
cryopreserved material. All six sperm users in treatment category 1
(40.0%)were treatedwith highly sterilizing chemotherapy and three
of them (20.0%) additionally underwentHSCT.Out of the five users
in category 2 (33.3%), three (20.0%) were treated with orchiectomy
and chemo-/chemoradiotherapy, and two (13.3%) exclusively with
chemotherapy. The three spermusers in category 3 (20.0%) received
less gonadotoxic agents and one of them (6.7%) had previously been
orchiectomized. One sperm user (6.7%) underwent radioiodine
therapy. No significant correlation between sperm usage and
diagnosis group was observed (Chi-square-test, p = 0.991).
The median storage time until the first material request was
26.0 months (IQR: 16.5 – 65.5 months). Most of those whoTABLE 1 | Respondents’ characteristics.
Characteristics
Age at time of survey, median (IQR) 38.0 (31.0 – 46.0)
Age at diagnosis, median (IQR) 27.0 (20.0 – 36.0)
Age at cryopreservation, median (IQR) 29.0 (20.0 – 36.0)
Marital status, n (%)
Single 32 (33.7)
Married 45 (47.4)




Reproductive material stored, n (%)
Ejaculated semen 82 (96.5)
Testicular tissue 3 (3.5)
N.a. 14
Time of cryopreservation, n (%)
Before treatment* 94 (94.9)
After treatment initialization 5 (5.1)*One of the patients did not undergo the planned gonadotoxic treatment.FIGURE 1 | Diagnoses of respondents. Values are presented as number of patients (%). One patient with other type of cancer was additionally diagnosed with
testicular cancer during the follow-up.November 2021 | Volume 11 | Article 772809
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first five years of storage. The highest number of sperm usages
was observed in the second year (six patients, 35.3%). During the
first 10 years of storage, 94.1% of the users requested their frozen
semen, and only one patient (5.9%) used his semen after a longer
storage time. He was 17 years old at the time of cryopreservation.
Among the non-users, 26 patients (34.7%) stated they would
potentially make use of their material in the future. 10 sperm
users (58.8%) achieved parenthood of at least one ART-
conceived child. However, seven patients (41.2%) reported they
had remained childless after unsuccessful ART procedures,
yielding a cumulative live-birth rate per couple of 58.8%. AllFrontiers in Oncology | www.frontiersin.org 5users had cryopreserved their semen prior to gonadotoxic
treatment except for one testicular cancer patient, whose sperm
cryopreservation was commissioned after orchiectomy. His ART
procedures remained unsuccessful. Analysis of storage periods
showed no significant difference in storage time between sperm
users with successful [20.0 months (IQR: 17.3 – 42.5 months)]
and unsuccessful ART outcomes [44.0 months (IQR: 15.0 – 116.0
months, Mann-Whitney-U-test, p = 0.261)]. The longest storage
time before sperm usage resulting in fatherhood was 78 months.
A total of 20 children were born from ART cycles (8
singletons and six pairs of twins). Additionally, one patient
stated he had an ART-conceived child from cryopreservedTABLE 2 | Treatment categories according to the gonadotoxic potential.
Treatment category Treatment or cytotoxic agent
Category 1: High gonadotoxicity HSCT conditioning (chemotherapy and/or TBI), BEACOPP, VAC
Category 2: Intermediate gonadotoxicity/risk for prolonged azoospermia Pelvic irradiation, cyclophosphamide, cisplatin, ifosfamide, lomustine, BEP, VIP, VIDE
Category 3: Low gonadotoxicity/risk for only temporary reduction in sperm counts Radical inguinal orchiectomy, vincristine, vinblastine, carboplatin, doxorubicin,
bleomycin, methotrexate, azathioprine, ABVD, CHOP
Category 4: Potential gonadotoxicity (existing data not sufficient) Rituximab, bendamustine, imatinib, cladribine, 131IodData from Poorvu et al. (28), additionally from Meistrich et al. (4), Vakalopoulos et al. (29), Traila et al. (30), and Zang et al. (31).
BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; VAC, vincristine, actinomycin D, cyclophosphamide; BEP, bleomycin,
etoposide, cisplatin; VIP, cisplatin, etoposide, ifosfamide; VIDE, vincristine, ifosfamide, doxorubicin, etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone.FIGURE 2 | Treatment categories and treatment types of respondents. Values are presented as number of patients (%). HSCTC, HSCT conditioning regimen.November 2021 | Volume 11 | Article 772809
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median age at the time of childbirth was 35.0 years (IQR: 32.0 –
36.0 years). One ART-conceived child (4.8%) suffered from a
pulmonary valve stenosis and one pair of twins (9.5%) was
reported deceased at the time of the survey. All the other
children (85.7%) were reported to be alive, healthy, and
normally developing. Birth weights and heights at birth are
tabulated in Table 5 (percentiles were incalculable due to
missing information on gestational age). Not all patients
provided the appropriate data.
Natural Fertility of Respondents
In total, 92 patients provided detailed data on their biological
children. 31 patients (33.8%) reported to have fathered at
least one child from natural conception, 8 patients (8.7%)
exclusively had ART-conceived children, and two patients
(2.2%) had children of unspecified type of reproduction. One
patient (1.1%) stated to have a pregnant partner at the time
of the survey and 50 patients (54.3%) reported to have no
biological children. Among those with naturally conceived
children, 12 patients had achieved parenthood before (13.1%),
9 patients after (9.8%), and 10 patients (10.9%) before as well
as after receiving gonadotoxic treatments. The first group
included three sperm users, the second and third group one
sperm user each. Table 4 illustrates diagnosis groups andFrontiers in Oncology | www.frontiersin.org 6treatment categories of patient groups who fathered and did
not father naturally conceived children after treatment. If
available, birth weights and heights at birth of naturally
conceived children after treatment are summarized in Table 5
(percentiles were incalculable due to missing information on
gestational age).DISCUSSION
In the present survey we reported on experiences of sperm
cryopreservation and outcomes of natural fertility in
oncological and non-oncological patients at the Cryobank of
Charité – Universitätsmedizin Berlin over a period of 22 years.
Our paper supplements findings to the existing data on
cryopreservation usage and success rates and is one of the first
to analyze the relation between gonadotoxic treatment types and
reproductive outcomes (19, 21–24).
Integration of Study Findings in the
Current State of Research
Our findings regarding patients’ characteristics and analysis of
pre-treatment semen parameters are mainly in line with those
presented by other authors. As already observed in previous
studies, oncological patients in this survey were most frequentlyTABLE 4 | Diagnosis groups and treatment categories of sperm users and non-users, and patients with and without naturally conceived children after gonadotoxic treatment.
Diagnosis group/treatment category Use of cryopreserved sperm Natural conception after treatment
Yes (n = 17) No (n = 82) Yes (n = 19) No (n = 73)
Diagnosis group
Testicular cancer 5 (29.4) 24 (29.3) 7 (36.8) 20 (27.4)
Non-testicular cancer 12 (70.6) 58 (70.7) 12 (63.2) 53 (72.6)
Leukemia 1 (5.9) 13 (15.9) 3 (15.8) 11 (15.1)
Lymphoma 6 (35.3) 20 (24.4) 5 (26.3) 19 (26.0)
Sarcoma 3 (17.6) 12 (14.6) 2 (10.5) 11 (15.1)
Other type of cancer 1 (5.9) 6 (7.3) 7 (9.6)
Autoimmune disease 1 (5.9) 7 (8.5) 2 (10.5) 5 (6.8)
Treatment category
Category 1: High gonadotoxicity 6 (40.0) 16 (21.9) 2 (12.5) 18 (27.3)
Category 2: Intermediate gonadotoxicity 5 (33.3) 35 (47.9) 5 (31.3) 32 (48.5)
Category 3: Low gonadotoxicity 3 (20.0) 13 (17.8) 4 (25.0) 12 (18.2)
Category 4: Potential gonadotoxicity 1 (6.7) 9 (12.3) 5 (31.3) 4 (6.1)
Treatment not realized 1 1
N.a. 2 8 3 6November 2021 | Volume 1Values are presented as number of patients (%).TABLE 3 | Pre-treatment semen characteristics at the time of cryopreservation according to diagnosis groups.
Diagnosis group Sperm concentration (106/ml) Progressive motility (%) Total motility (%)
Testicular cancer 18.0 (9.7 – 37.8) 48.0 (23.0 – 55.0) 56.0 (35.0 – 65.0)
Non-testicular cancer 54.2 (23.0 – 110.2) 46.0 (32.0 – 55.8) 56.0 (44.0 – 65.5)
Leukemia 43.0 (22.7 – 118.2) 44.0 (33.0 – 54.0) 54.0 (47.0 – 64.0)
Lymphoma 33.0 (14.0 – 91.8) 50.0 (30.0 – 54.8) 56.5 (39.8 – 66.0)
Sarcoma 58.8 (19.1 – 171.0) 45.0 (31.5 – 50.5) 55.0 (42.5 – 63.5)
Other type of cancer 51.0 (22.7 – 138.0) 32.5 (28.0 – 59.5) 43.0 (30.0 – 62.0)
Autoimmune disease 97.6 (68.7 – 224.6) 61.5 (52.5 – 68.3) 66.5 (59.3 – 73.8)Values are presented as median (IQR).1 | Article 772809
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and hematopoietic tissue (1, 9, 13, 15, 17–20). Although our
analysis of pre-treatment semen parameters at the time of
cryopreservation showed a huge interindividual variability, the
lowest median sperm count was observed in patients with
malignant testis tumors. Similar findings were reported by
other authors (1, 5, 15, 17, 18, 20). Factors impairing
spermatogenesis caused by testicular tumors even prior to
treatment initiation seem to be multifactorial, including direct
parenchymal damage and replacement by the malignancy,
interferences in the hypothalamic-pituitary-gonadal axis,
systemic inflammation, and increased oxidative stress (6).
The sperm usage rate in our study (17.2%) was higher
compared to the 3 – 10% experienced by most of the other
clinics (1, 9, 13–15, 20). For example, Ferrari and colleagues
calculated in their review an aggregated usage rate of 8% (30
studies included) (16). However, a much higher usage rate of
27% was reported by Hammarberg and colleagues, who
performed a cross-sectional survey (19). In contrast, the live-
birth rate per couple we observed (58.8%) corresponds to
findings reported in previous studies, even though the rates for
each study vary strongly (35 – 80%) (1, 14, 19, 20). Nevertheless,
when comparing the usage and ART success rates in our cohort
to other results, the number of patients and a possible
participation bias should be considered.
Variables Affecting Sperm Usage
Although the usage rate in the present study was a bit higher
compared to previous, it remained relatively low. In the
following, we want to discuss on some variables that may affect
the number of sperm usages:
Period of follow-up: Some authors suggested that sperm usage
might increase with longer follow-up (16, 17, 32). However, our
results did not confirm this (94.1% of the sperm users requested
their material within the first 10 years of storage). Similarly, in
their latest study, Ferrari and colleagues showed only a marginal
increase in the usage rate (from 9.4% to 12.0%) by extending the
period of follow-up beyond 10 years (18).
Type of gonadotoxic treatment: 40.0% of the sperm users
compared to only 21.9% of the non-users in our cohort received
highly sterilizing treatments. This observation indicates that
treatments with strong gonadotoxicity might represent a
predictive factor for future sperm usage even though our
sample sizes were too small to apply reliable statistical tests to
show the correlation. To our knowledge, the relation between
different types of treatment and usage of cryopreserved sperm
has not yet been analyzed sufficiently and, hence, further
research is necessary to confirm our results.Frontiers in Oncology | www.frontiersin.org 7Outcomes of natural reproduction: One of the reasons for low
sperm usage rates could be maintained or recovered fertility.
Given that 20.7% of our patients reported to have fathered
children from natural conception after treatment, a substantial
proportion of patients have retained or retrieved fertility.
Nevertheless, two of them used their cryopreserved sperm.
More research is needed to draw further conclusions on this
aspect (19).
Costs for storage: Since, in some countries, the costs of
cryopreserving reproductive material are born by patients
themselves, they may affect cryopreservation rates and future
sperm usage. However, no consistent data on this regard exists
(11, 12). In Germany, since the beginning of July 2021, Public
Health Insurance covers the costs for cryopreservation,
specifically for male cancer patients under 50 years to preserve
ejaculated sperm or testicular tissue when undergoing fertility-
damaging therapies. Previously, such patients had to bear the
costs privately and some may have chosen not to cryopreserve or
to maintain the storage for this reason. It remains to be seen to
what extent the alteration in insurance coverage will influence
sperm cryopreservation, storage, and usage rates.
Future Perspectives
The gonadotoxic potential of many commonly used
chemotherapeutics is still not definitely explored. Despite this,
we want to raise the topic of modern, targeted therapies and their
impact on the male reproductive system as an important
direction for future research. The effects of targeted therapies
on male fertility are poorly investigated, and some of those agents
could be less damaging compared to classical chemo- and
radiotherapy regimes. So far, studies exploring the harmful
effects on spermatogenesis caused by the tyrosine kinase
inhibitor imatinib have demonstrated controversial outcomes.
Fertility impairments might be only modest in adult males or
more severe when the agent is given during puberty (4). Since the
use of targeted therapies in cancer therapy is increasing recently,
their impact on fertility should be addressed in future research.
Limitations
We are aware of the shortcomings and limitations of the present
study. Even though the initial number of considered sperm
banking patients was high (1089 patients), the survey had a
relatively small number of participants and reported sperm
usages. Due to the low response rate of 21.5%, participation
bias may have an influence on our findings. It is not possible to
predict how these outcomes would have differed with a larger
study cohort. Further limitations are found in the lack of
information about semen characteristics after treatment, detailsTABLE 5 | Birth weights and heights of newborns.
Newborns Birthweight (grams) Height at birth (cm)
All newborns 3300.0 (2765.0 – 3660.0) 52.0 (49.0 – 53.0)
ART-conceived twins 1950.0 (1470.0 – 2330.0) 45.5 (41.5 – 47.5)
ART-conceived singletons 3050.0 (2882.5 – 3355.0) 52.0 (50.5 – 53.0)
Naturally conceived twins after treatment 1870.0 44.5
Naturally conceived singletons after treatment 3570.0 (3140.0 – 3910.0) 52.0 (50.0 – 54.0)November 2021 | VolumValues are presented as median (IQR).e 11 | Article 772809
Lackamp et al. Sperm Cryopreservation Experiences and Outcomeson ART procedures, and pregnancy attempts. The study also has
a retrospective design, our questionnaire was not validated
previously, and most of the information was self-reported by
the patients. Due to these limitations, our study findings should
be interpreted with caution and might be more indicative
than generalizable.
Implications
The findings presented in this study affirm that the
cryopreservation of sperm is an effective fertility preservation
method for male patients treated with gonadotoxic therapies and
that more than half of the patients achieve parenthood by using
the cryopreserved material. Our results may serve a practical
application for health care providers and their patients when
discussing the possible benefits of fertility preservation programs.
Moreover, our data indicates that treatments with high
gonadotoxicity might represent a predictive factor for future
sperm usage and may encourage patients to store reproductive
material, especially before undergoing treatments with a high
risk for fertility loss. Given that the group of sperm users
reported in this study consisted of oncological as well as non-
oncological patients, the results emphasize the importance that
cryopreservation should be offered to all patients before initiating
a fertility-damaging therapy.DATA AVAILABILITY STATEMENT
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